Given that 25% of AML and about 10% of MPN and MDS bare DNMT3A mutations, which are associated with increased risk of relapse and poor overall prognosis; being able to target DNMT3A and downstream signals from DNMT3A is a prudent therapeutic approach. This evidence concerns the gene DNMT3A and myeloproliferative disorder.